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Abstract
Carcinoid heart disease is a rare complication of an already rare disease. This issue is theorized to be
secondary to released proinflammatory molecules that deposit on the surfaces of heart valves. These
molecules are released from the carcinoid tumor itself and manifest symptoms based on liver, lung and
brain function. The detection of 5-HIAA, a breakdown source of serotonin, is useful for diagnosis. These
deposits occur most commonly on the endocardium of valvular cusps and cardiac chambers. This case
presents a 48 year old woman with echo findings of right heart failure in the setting of a carcinoid tumor.
It is important for early recognition and treatment of cardiac lesions to prevent worsening heart failure.
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CASE REPORT

Management of Right Sided Carcinoid Heart Failure
Ganesh Arun*, Ismat Cheema, Lorrie Pennﬁeld, Mohammed Raza, Erik Raborn,
Ami Patel, Farhan Ali
Arnot Ogden Medical Center, USA

Abstract
Carcinoid heart disease is a rare complication of an already rare disease. This issue is theorized to be secondary to
released proinﬂammatory molecules that deposit on the surfaces of heart valves. These molecules are released from the
carcinoid tumor itself and manifest symptoms based on liver, lung and brain function. The detection of 5-HIAA, a
breakdown source of serotonin, is useful for diagnosis. These deposits occur most commonly on the endocardium of
valvular cusps and cardiac chambers. This case presents a 48 year old woman with echo ﬁndings of right heart failure in
the setting of a carcinoid tumor. It is important for early recognition and treatment of cardiac lesions to prevent worsening heart failure.
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1. Introduction

C

arcinoid heart disease is a rare disease
affecting 50% of patients with systemic carcinoid syndrome.1 The likely mechanism is multifaceted including release of vasoactive chemicals such
as serotonin, prostaglandins, histamine, bradykinins, and tachykinins.1 These substances deposit on
the endocardial valve surfaces, causing dysfunction
of the valves. Serotonin is normally cleared by the
liver, lung, and brain but the overwhelmed system
causes deposition into the heart valves.2 This is
particularly the case in cirrhotic and lung pathology
patients. The breakdown of serotonin can be
measured to estimate the overall burden.2 This case
presents a 48-year-old woman with new echo ﬁndings compatible with right heart failure secondary to
carcinoid syndrome.

2. Case presentation
A 48-year-old woman with a past medical history
of hypothyroidism presented with dyspnea for the
last month. Denies any productive cough, sick contacts, fevers, or chills. She endorsed diffuse redness

on her face and right arm. Anti-streptolysin A
returned positive and therefore completed a 10-day
course of cephalexin. Unfortunately, no resolution
of symptoms. Other related symptoms included
abdominal distress, non-bloody diarrhea and
tachycardia. She lost approximately 30 pounds in
the past 2 months due to chronic diarrhea. Recent
celiac serology testing returned negative. CT
Abdomen and Pelvis with contrast showed a
prominent and speculated nodal mass at the root of
the mesentery with focal nodular thickening of the
duodenal wall. Of note, the adrenals were unremarkable, and no other masses were seen.
Lab results
Urinary 5-HIAA returned at
40mg/24hr
Urinary Epinephrine
returned 540 mcg/24 hr
Urinary Norepinephrine 1070
mcg/24hr
Dopamine 162 mcg/24hr

(Reference <30 mg/24hr)
(Reference 10 to 200 mcg/24hr)
(Reference 80 to 520 mcg/24hr)
(Reference 0 to 20 mcg/24 hr)

Echo revealed Ejection Fraction 60e65% grade 1
diastolic dysfunction with Moderate Tricuspid
Regurgitation. Diagnosed with right heart failure
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secondary to carcinoid syndrome. For blood pressure
and volume status control, furosemide was started.
Octreotide decreases the systemic surge of serotonin.
Her symptoms improved and followed in the outpatient for heart failure. She is scheduled for resection of
a carcinoid tumor from the duodenal wall.

4. Discussion
Carcinoid syndrome is a tumor of well-differentiated endocrine and neuro cells that comprise the
gastroenterology and pulmonary systems.2 There is
a mass production of vasodilatory molecules that
cause systemic symptoms. These tumor products
cause a constellation of symptoms known as carcinoid syndrome.3 Neuroendocrine tumors present in
the digestive tract, lungs, and less commonly ovaries
and kidneys. Other locations include the rectum,
appendix, colon, and stomach.4 The differential includes alternative tumors secreting catecholamines.
This is ruled out in our case because CT abdomen
and pelvis with contrast did not reveal any mass on
the adrenals. In addition, the cardiac manifestations
would be unusual in pheochromocytoma.5
Clinical features6
Cutaneous ﬂushing
Venous telangiectasias
Secretory diarrhea
Bronchospasm
Wheezing/Dyspnea

Appears in late course carcinoid
syndrome
Occurs in about 80% of patients
Occurs in 10e20% of patients
Occurs along with ﬂushing episodes
Clinical hallmark in about 85% of
patients

The valvular lesions in the heart are represented
by ﬁbrous plaques deposited on the endocardial
surface.6 The cardiac chambers and the intima of
pulmonary arteries and aorta are the prime targets
for inﬂammatory markers.6 The right sided valves
are affected ﬁrst due to the closest area of involvement. The left sided valves are unaffected due to
inactivation of vasoactive substances through the
pulmonary system.7 The other systemic symptoms
include pellagra, ﬂushing, and bronchospasm.8 The
manifestations of these symptoms are based on
quantitative amounts of vasoactive substances in the
blood stream.9
Carcinoid tumors one to two cm in size, fullthickness surgical removal is optimal to prevent
leftover of progressive symptoms.10 Lesions larger
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than two cm also has full-thickness removal with
addition of regional lymphadenectomy to decrease
spread. These measures decrease the chance of
carcinoid crisis.11

5. Conclusion
Early treatment and diagnosis of heart lesions will
decrease the vasoactivity of these molecules on the
heart valves.2 The overﬂow of biologically active
compounds from the tumor increases the risk for
blood pressure ﬂuctuations and worsening heart
failure symptoms.
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